4 ms·

Does anyone know if they publish details about the size/strength of the effect anywhere or a link to the actual numbers for the study population?

• lanewinfield 7y ago
  Looks like it "works" (2-hour pain free marker) for ~10% of people. https://www.evaluate.com/vantage/articles/news/snippets/ubrelvys-winner-not-long https://www.evaluate.com/vantage/articles/news/snippets/ubre...
  • nharada 7y ago
    It might not sound impressive, but I think this is great news for two reasons: 1) Even if only 10% of people respond, this is likely going to give thousands of people for whom nothing else works a drug that actually does something. 2) Nearly all existing migraine meds fall into the "triptan" class of drugs. This is an entirely new class (CGRP antagonist), and may pave the way to new treatments even if this specific iteration isn't as effective as future ones.
    • ekianjo 7y ago
      for 2), this is not news, back in October 2019 Lilly got their drug approved as well in this class: https://www.bloomberg.com/news/articles/2018-09-28/eli-lilly-migraine-drug-approved-and-will-be-free-to-patients https://www.bloomberg.com/news/articles/2018-09-28/eli-lilly...
      • Tharkun 7y ago
        The news here is that ubrogepant is a tablet taken as an abortive, while emgality etc are injections taken as a preventative.